Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2014 - 2026)

Aclaris Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $664000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 75.41% year-over-year to $664000.0; the TTM figure through Mar 2026 stood at $664000.0 (down 75.41% YoY), while the FY2025 annual figure was $504000.0, down 17.24% from the prior year.
• Other Accumulated Expenses was $664000.0 for Q1 2026 at Aclaris Therapeutics, up from $504000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.7 million in Q2 2025 to a low of $217000.0 in Q4 2022.
• Historically, Other Accumulated Expenses has averaged $1.2 million across 5 years, with a median of $664000.0 in 2026.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses slumped 87.49% in 2022, then jumped 374.56% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $217000.0 in 2022, then surged by 31.34% to $285000.0 in 2023, then soared by 113.68% to $609000.0 in 2024, then decreased by 17.24% to $504000.0 in 2025, then soared by 31.75% to $664000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $664000.0 (Q1 2026), $504000.0 (Q4 2025), and $387000.0 (Q3 2025), per Business Quant data.